Allarity Therapeutics, Inc. (NASDAQ: ALLR) filed a Current Report on Form 8-K dated September 30, 2026, providing an update on its proprietary Drug Response Predictor (DRP) technology, patent portfolio, and in-house laboratory capabilities. The company stated that these advances are intended to support the clinical development of its lead asset, stenoparib (2X-121), and expand potential external partnership opportunities.
The report highlights that Allarity has recently secured new patent awards and achieved CLIA certification for its in-house laboratory. The company asserts that these developments allow it to extend the utility of its stenoparib-DRP test as a companion diagnostic and retain sole control over the clinical testing process. This is intended to extend the commercial viability of both stenoparib and the associated diagnostic test.
According to the filing, the stenoparib-DRP is based on a unique 414-gene expression signature, which includes genes associated with WNT pathway activity. The company notes that an exploratory analysis of a prior Phase 2 cohort of patients with advanced ovarian cancer treated with twice-daily stenoparib was presented at the AACR 2026 meeting. The analysis reportedly showed that higher pretreatment DRP scores were associated with longer overall survival.
Allarity states that these developments support its strategy to use DRP to inform patient selection for a pivotal trial of stenoparib. The company is currently advancing the clinical development of stenoparib toward potential FDA approval. The filing also references ongoing trials, including a protocol focused on patients with platinum-resistant ovarian cancer that began enrolling in the summer of 2025, and a Phase 2 trial evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer that began enrolling in early 2026.
